{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["cancer", "complementary and alternative medicine", "gynecologic oncology", "herbal medicine", "integrative medicine"]], "GeneralNote": [], "OtherAbstract": [{"AbstractText": ["<b>Hintergrund</b> Immer mehr Informationen zu integrativer und komplement\u00e4rer Medizin sind verf\u00fcgbar, besonders f\u00fcr Krebspatienten. Noch ist aber wenig \u00fcber die Verwendung von pflanzlichen Arzneimitteln durch Patientinnen mit gyn\u00e4kologischem Krebs bekannt. Ziel dieser Studie war es, mehr \u00fcber die Verwendung pflanzlicher Mittel durch Patientinnen mit gyn\u00e4kologischem Krebs im Vergleich mit einer gesunden Kontrollgruppe zu erfahren. <b>Methoden</b> Diese Querschnittsuntersuchung wurde an der Abteilung f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Universit\u00e4tsklinikum Erlangen durchgef\u00fchrt. 201 Patientinnen mit gyn\u00e4kologischem Krebs und 212 gesunde Kontrollpersonen wurden in die Studie aufgenommen. Die Verwendung von pflanzlichen Arzneimitteln wurde anhand eines standardisierten Fragenbogens evaluiert. Die medizinischen Daten zu den Krebspatientinnen wurden den Krankenhausakten entnommen. Gruppenvergleiche wurden mithilfe eines logistischen Regressionsmodells durchgef\u00fchrt. Ein Poisson-Regressionsmodell wurde verwendet, um Risikoquoten auszuwerten. <b>Ergebnisse</b> Patientinnen mit gyn\u00e4kologischem Krebs verwendeten pflanzliche Arzneimittel signifikant weniger als die gesunden Frauen in der Kontrollgruppe. 69% der Patientinnen mit gyn\u00e4kologischem Krebs und 81% der gesunden Teilnehmerinnen gaben an, pflanzliche Produkte zu benutzen. 40% der Krebspatientinnen und 56% der gesunden Personen gaben an, dass sie pflanzliche Produkte f\u00fcr medizinische Zwecke verwendeten. Die Behandlung von krebsbedingten Symptomen war einer der von den Krebspatientinnen angegebenen Gr\u00fcnde f\u00fcr die Verwendung von pflanzlichen Arzneimitteln. Die Hauptinformationsquellen f\u00fcr beide Gruppen waren Familie und Freunde. <b>Schlussfolgerungen</b> Obwohl pflanzliche Arzneimittel weniger oft von Patientinnen mit gyn\u00e4kologischem Krebs eingenommen werden, verwenden sowohl Krebspatientinnen als auch gesunde Personen pflanzliche Produkte. Um Krebspatientinnen eine optimale Therapie zu erm\u00f6glichen, sollten Onkologen \u00fcber die von ihren Patientinnen verwendeten pflanzlichen Mittel informiert werden, damit sie die zur Selbstbehandlung verwendeten pflanzlichen Arzneimittel ber\u00fccksichtigen k\u00f6nnen. Eine Beratung zum Einsatz von pflanzlichen Arzneimitteln durch den Onkologen sollte gef\u00f6rdert werden."], "CopyrightInformation": "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ )."}], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34168382", "DateRevised": {"Year": "2021", "Month": "06", "Day": "26"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "06", "Day": "21"}], "Language": ["eng"], "ELocationID": ["10.1055/a-1487-6284"], "Journal": {"ISSN": "0016-5751", "JournalIssue": {"Volume": "81", "Issue": "6", "PubDate": {"Year": "2021", "Month": "Jun"}}, "Title": "Geburtshilfe und Frauenheilkunde", "ISOAbbreviation": "Geburtshilfe Frauenheilkd"}, "ArticleTitle": "Patterns and Trends of Herbal Medicine Use among Patients with Gynecologic Cancer.", "Pagination": {"StartPage": "699", "EndPage": "707", "MedlinePgn": "699-707"}, "Abstract": {"AbstractText": ["<b>Background</b> More and more information about complementary and integrative medicine is becoming available, especially among cancer patients. However, little is known about the use of herbal medicine by patients with gynecologic cancers. This study aimed to assess the use of herbal products by gynecologic cancer patients compared with healthy controls. <b>Methods</b> This cross-sectional study was conducted at the Department for Gynecology and Obstetrics of Erlangen University Hospital and included 201 patients with gynecologic cancer and 212 healthy controls. Use of herbal medicines was evaluated using a standardized questionnaire. Medical information on cancer patients was collected from hospital records. Group comparisons were done using a logistic regression model. Risk ratios were assessed using a Poisson regression model. <b>Results</b> Gynecologic cancer patients used herbal medicine significantly less often than healthy persons. 69% of gynecologic cancer patients and 81% of healthy participants reported using herbal products. 40% of cancer patients and 56% of healthy persons reported using plants for medicinal purposes. Motives of cancer patients for using herbal medicine included treatment of cancer-related symptoms. The major source of information for both groups was family and friends. <b>Conclusions</b> Although herbal medicine was used less by patients with gynecologic cancer, herbal products were used by both cancer patients and healthy individuals. To provide cancer patients with optimal therapy, oncologists should be informed about the herbal products used by their patients as this will allow them to take their patients' self-medication with herbal medicine into account. Counseling by oncologists on the use of herbal medicine should be encouraged."], "CopyrightInformation": "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ )."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute for Women's Health/Institut f\u00fcr Frauengesundheit GmbH, Erlangen, Germany."}], "LastName": "Theuser", "ForeName": "Anna-Katharin", "Initials": "AK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen - European Metropolitan Area Nuremberg (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany."}], "LastName": "Hack", "ForeName": "Carolin C", "Initials": "CC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen - European Metropolitan Area Nuremberg (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany."}], "LastName": "Fasching", "ForeName": "Peter A", "Initials": "PA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen - European Metropolitan Area Nuremberg (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany."}], "LastName": "Antoniadis", "ForeName": "Sophia", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen - European Metropolitan Area Nuremberg (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany."}], "LastName": "Grasruck", "ForeName": "Katharina", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen - European Metropolitan Area Nuremberg (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany."}], "LastName": "Wasner", "ForeName": "Sonja", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen - European Metropolitan Area Nuremberg (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany."}], "LastName": "Knoll", "ForeName": "Stefanie", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "PhytoLab GmbH & Co. KG, Vestenbergsgreuth, Germany."}], "LastName": "Sievers", "ForeName": "Hartwig", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen - European Metropolitan Area Nuremberg (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany."}], "LastName": "Beckmann", "ForeName": "Matthias W", "Initials": "MW"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Gynecology and Obstetrics, Alb Fils Kliniken, Klinik am Eichert, G\u00f6ppingen, Germany."}], "LastName": "Thiel", "ForeName": "Falk C", "Initials": "FC"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Geburtshilfe Frauenheilkd", "NlmUniqueID": "0370732", "ISSNLinking": "0016-5751"}, "CoiStatement": "Conflict of Interest AKT received a research grant from Phytolab GmbH & Co KG. CCH has received honoraria from Roche and Novartis. PAF reports personal fees from Novartis, grants from BioNtech, personal fees from Pfizer, personal fees from Daiichi Sankyo, personal fees from AstraZeneca, personal fees from Eisai, personal fees from Merck Sharp & Dohme, grants from Cepheid, personal fees from Lilly, personal fees from Pierre Fabre and personal fees from Seattle Genetics. All of the other authors declare that they have no conflicts of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Molassiotis A, Browall M, Milovics L. Complementary and alternative medicine use in patients with gynecological cancers in Europe. Int J Gynecol Cancer. 2006;16 01:219\u2013224.", "ArticleIdList": ["16515594"]}, {"Citation": "Swisher E M, Cohn D E, Goff B A. Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol. 2002;84:363\u2013367.", "ArticleIdList": ["11855870"]}, {"Citation": "Navo M A, Phan J, Vaughan C. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol. 2004;22:671\u2013677.", "ArticleIdList": ["14966090"]}, {"Citation": "Ben-Arye E, Schiff E, Steiner M. Attitudes of Patients With Gynecological and Breast Cancer Toward Integration of Complementary Medicine in Cancer Care. Int J Gynecol Cancer. 2012;22:146\u2013153.", "ArticleIdList": ["21912265"]}, {"Citation": "Gratus C, Wilson S, Greenfield S M. The use of herbal medicines by people with cancer: a qualitative study. BMC Complement Altern Med. 2009;9:14.", "ArticleIdList": ["PMC2685766", "19442268"]}, {"Citation": "Goldstein M S, Lee J H, Ballard-Barbash R. The use and perceived benefit of complementary and alternative medicine among Californians with cancer. Psychooncology. 2008;17:19\u201325.", "ArticleIdList": ["17410526"]}, {"Citation": "World Health Organization (WHO)  Traditional Medicine: Definitions 2017. Accessed June 30, 2020 at:http://www.who.int/medicines/areas/traditional/definitions/en/"}, {"Citation": "Arzneimittelgesetz (AMG) . 1967. Medicinal Products Act in the version published on 12 December 2005 (Federal Law Gazette [BGBl.]) Part I p. 3394, last amended by Article 11 of the Act of 6 May 2019 (Federal Law Gazette I p. 646)"}, {"Citation": "Bundesverband der Arzneimittel-Hersteller e.V. (BAH)  Der Arzneimittelmarkt in Deutschland 2019. The German Pharmaceutical Market 2019 2020. Accessed August 11, 2020 at:https://www.bah-bonn.de/publikationen/zahlen-fakten/"}, {"Citation": "European Medicines Agency  Committee on Herbal Medicinal Products  Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products. 2016. EMA/HMPC/71049/2007 Rev. 2Accessed November 17, 2020 at:https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-ctd-format-preparation-registration-application-traditional-herbal-medicinal-products_en.pdf"}, {"Citation": "European Medicines Agency  Committee on Herbal Medicinal Products  Guideline on non-clinical documentation in applications for marketing authorisation/registration of well-established and traditional herbal medicinal products. 2018. EMEA/HMPC/32116/2005 Rev.1Accessed November 17, 2020 at:https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-documentation-applications-marketing-authorisation/registration-well-established-traditional-herbal-medicinal-products-revision-1_en.pdf"}, {"Citation": "European Medicines Agency  Committee on Herbal Medicinal Products  Committee for Medicinal Products for Human Use  Committee for Medicinal Products for Veterinary Use  Guideline on quality of herbal medicinal products/traditional herbal medicinal products. 2011. EMA/CPMP/QWP/2819/00 Rev. 2, EMA/CVMP/814/00 Rev. 2, EMA/HMPC/201116/2005 Rev. 2Accessed November 17, 2020 at:https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-herbal-medicinal-products-traditional-herbal-medicinal-products-revision-2_en.pdf"}, {"Citation": "European Parliament and Council . Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements (Text with EEA relevance). Official Journal of the European Communities 2002. L183, 12/07/2002 P. 0051 \u2013 0057"}, {"Citation": "Arslan D, Tural D, Akar E. Herbal administration and interaction of cancer treatment. J Palliat Med. 2013;16:1466\u20131476.", "ArticleIdList": ["24102459"]}, {"Citation": "Izzo A A, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69:1777\u20131798.", "ArticleIdList": ["19719333"]}, {"Citation": "Clairet A L, Boiteux-Jurain M, Curtit E. Interaction between phytotherapy and oral anticancer agents: prospective study and literature review. Med Oncol. 2019;36:45.", "ArticleIdList": ["30993543"]}, {"Citation": "Hartkopf A D, M\u00fcller V, W\u00f6ckel A. Translational Highlights in Breast and Ovarian Cancer 2019 \u2013 Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6\u2009Therapy. Geburtshilfe Frauenheilkd. 2019;79:1309\u20131319.", "ArticleIdList": ["PMC6924326", "31875860"]}, {"Citation": "Deng G, Cassileth B R, Yeung K S.Complementary therapies for cancer-related symptoms J Support Oncol 20042419\u2013426.discussion 427\u2013429", "ArticleIdList": ["15524070"]}, {"Citation": "Shim J M, Schneider J, Curlin F A. Patterns of User Disclosure of Complementary and Alternative Medicine (CAM) Use. Med Care. 2014;52:704\u2013708.", "ArticleIdList": ["25025870"]}, {"Citation": "Drozdoff L, Klein E, Kalder M. Potential Interactions of Biologically Based Complementary Medicine in Gynecological Oncology. Integr Cancer Ther. 2019;18:1.534735419846392E15.", "ArticleIdList": ["PMC6501502", "31046491"]}, {"Citation": "Drozdoff L, Klein E, Kiechle M. Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy. BMC Complement Altern Med. 2018;18:259.", "ArticleIdList": ["PMC6154925", "30249217"]}, {"Citation": "on behalf of the Working Group Prevention and Intergrative Oncology of the German Cancer Society J . Henf A, Wesselmann S, Huthmann D. Complementary and Alternative Medicine in German Cancer Centers. Oncol Res Treat. 2014;37:390\u2013394."}, {"Citation": "Schuerger N, Klein E, Hapfelmeier A. Evaluating the Demand for Integrative Medicine Practices in Breast and Gynecological Cancer Patients. Breast Care. 2019;14:35\u201340.", "ArticleIdList": ["PMC6465704", "31019441"]}, {"Citation": "Zeller T, Muenstedt K, Stoll C. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol. 2013;139:357\u2013365.", "ArticleIdList": ["23099993"]}, {"Citation": "Robert Koch-Institut (RKI)  Bericht zum Krebsgeschehen in Deutschland 2016. Accessed September 15, 2020 at:https://edoc.rki.de/handle/176904/3264"}, {"Citation": "Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft; Deutsche Krebshilfe, AWMF)  S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom Langversion 1.0. Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level), Long Version 1.0. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) e.V. 2018Accessed June 15, 2020 at:https://www.awmf.org/uploads/tx_szleitlinien/032-034OLl_S3_Endometriumkarzinom-Diagnostik-Therpie-Nachsorge_2018-04.pdf"}, {"Citation": "Emons G, Steiner E, Vordermark D. Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) \u2013 Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities. Geburtshilfe Frauenheilkd. 2018;78:1089\u20131109.", "ArticleIdList": ["PMC6261739", "30581199"]}, {"Citation": "Schn\u00fcrch H G, Ackermann S, Alt-Radtke C D. Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No.\u2009032/042, October 2018) Geburtshilfe Frauenheilkd. 2019;79:1060\u20131078.", "ArticleIdList": ["PMC6820713", "31680701"]}, {"Citation": "Deutschen Krebsgesellschaft e.V. und Deutschen Krebshilfe e.V.  Leitlinienprogramm Onkologie der A WMF.S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Ovarian Cancer. Guideline (S3-Level). Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) e.V. 2016Accessed February 01, 2018 at:https://www.ago-online.de/fileadmin/downloads/leitlinien/ovar/S3-Ovarialkarzinom-OL-Langversion.pdf"}, {"Citation": "Barnes B, Kraywinkel K, Nowossadeck E, Sch\u00f6nfeld I, Starker A, Wienecke A, Wolf U.Bericht zum Krebsgeschehen in Deutschland 2016 Berlin: Robert Koch-Institut; 2016https://edoc.rki.de/handle/176904/3264Accessed September 15, 2020 at:"}, {"Citation": "European Parliament and Council . Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union 2004. OJ L136, 30.4.2004, p. 85 \u2013 90"}, {"Citation": "EFSA Scientific Committee . Guidance on safety assessment of botanicals and botanical preparations intended for use as ingredients in food supplements. EFSA Journal. 2009;7:1249."}, {"Citation": "WHO Expert Committee on Specifications for Pharmaceutical Preparation  Annex1 WHO guidelines on good herbal processing practices for herbal medicines. WHO Technical Report Series, No 1010, Fifty-second report: 81 \u2013 151 2018. Accessed April 15, 2020 at:https://www.who.int/traditional-complementary-integrative-medicine/publications/trs1010_annex1.pdf"}, {"Citation": "Corner J, Yardley J, Maher E J. Patterns of complementary and alternative medicine use among patients undergoing cancer treatment. Eur J Cancer Care (Engl) 2009;18:271\u2013279.", "ArticleIdList": ["19432919"]}, {"Citation": "Hack C C, Voi\u00df P, Lange S. Local and Systemic Therapies for Breast Cancer Patients: Reducing Short-term Symptoms with the Methods of Integrative Medicine. Geburtshilfe Frauenheilkd. 2015;75:675\u2013682.", "ArticleIdList": ["PMC4520960", "26257404"]}, {"Citation": "Molassiotis A, Scott J A, Kearney N. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer. 2006;14:260\u2013267.", "ArticleIdList": ["16143871"]}, {"Citation": "Wiedeck C, Klein E, Hapfelmeier A. Pr\u00e4valenz und Pr\u00e4diktoren f\u00fcr die Nicht-Anwendung komplement\u00e4rmedizinischer Therapien bei Patientinnen mit Mamma- oder gyn\u00e4kologischen Krebserkrankungen. Geburtshilfe Frauenheilkd. 2018;78:616."}, {"Citation": "Barnes J, Anderson L A, Phillipson J D. London, Chicago: Pharmaceutical Press; 2007. Herbal Medicines."}, {"Citation": "Beitz R, Doren M, Knopf H. [Self-medication with over-the-counter (OTC) preparations in Germany] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004;47:1043\u20131050.", "ArticleIdList": ["15549197"]}, {"Citation": "Eickhoff C, Hammerlein A, Griese N. Nature and frequency of drug-related problems in self-medication (over-the-counter drugs) in daily community pharmacy practice in Germany. Pharmacoepidemiol Drug Saf. 2012;21:254\u2013260.", "ArticleIdList": ["21953893"]}, {"Citation": "Vickers K A, Jolly K B, Greenfield S M. Herbal medicine: women\u02bcs views, knowledge and interaction with doctors: a qualitative study. BMC Complement Altern Med. 2006;6:40.", "ArticleIdList": ["PMC1702550", "17156416"]}, {"Citation": "Harrigan J T. Patient disclosure of the use of complementary and alternative medicine to their obstetrician/gynaecologist. J Obstet Gynaecol. 2011;31:59\u201361.", "ArticleIdList": ["21280996"]}, {"Citation": "Von Gruenigen V E, White L J, Kirven M S. A comparison of complementary and alternative medicine use by gynecology and gynecologic oncology patients. Int J Gynecol Cancer. 2001;11:205\u2013209.", "ArticleIdList": ["11437926"]}, {"Citation": "Hack C C, Fasching P A, Fehm T. Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Integr Cancer Ther. 2017;16:165\u2013175.", "ArticleIdList": ["PMC5739129", "27627986"]}, {"Citation": "Piersen C E. Phytoestrogens in botanical dietary supplements: implications for cancer. Integr Cancer Ther. 2003;2:120\u2013138.", "ArticleIdList": ["15035899"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "1", "Day": "28"}, {"Year": "2021", "Month": "4", "Day": "20"}, {"Year": "2021", "Month": "6", "Day": "25", "Hour": "6", "Minute": "46"}, {"Year": "2021", "Month": "6", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "6", "Day": "26", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "6", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34168382", "PMC8216777", "10.1055/a-1487-6284", "14876284"]}}], "PubmedBookArticle": []}